53 /100
HIGH RISK
Score updated May 30, 2026

OKUR — OnKure Therapeutics, Inc. Dilution Risk Tracker

Track OKUR dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track OKUR — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
70
💰 Cash Runway
0
📊 Float Risk
52
⚠️ Warrant Exposure
70
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
36%
📜 Warrant Exercise 40%
• Significant warrants: 23% of shares outstanding
• Elevated warrant risk score (70/100)
📉 Score Deterioration 40%
• Score rose 29 points recently (worsening)
💰 Capital Raise 20%
• Active shelf registration ($150M, 88% of market cap)
🔔 Track OKUR — Get forecast alerts →

💹 Market Data

Market Cap$169.66M
Shares Outstanding40.40M
Float17.50M
Cash$192.11M
Debt$409.0K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 27.5% shares (2025Q4 vs prior)
42 institutional holders · 13.04M shares
#1 ACORN CAPITAL ADVISORS, LLC 2.84M shares
#2 ADAR1 Capital Management, LLC 2.03M shares
#3 CANTOR FITZGERALD, L. P. 1.43M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest199.4K
Days to Cover1.4
% of Float1.0%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2024
S-3 SHELF Apr 24, 2026
3 FORM3 Apr 07, 2026
4 INSIDER TRANSACTION Apr 03, 2026
4 INSIDER TRANSACTION Apr 03, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track OKUR Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking OKUR — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for OKUR
📊 OKUR FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 OKUR Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.